BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2650722)

  • 1. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.
    Adams M; Kerby IJ; Rocker I; Evans A; Johansen K; Franks CR
    Acta Oncol; 1989; 28(1):57-60. PubMed ID: 2650722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
    Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
    J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
    Gurney H; Crowther D; Anderson H; Murphy D; Prendiville J; Ranson M; Mayor P; Swindell R; Buckley CH; Tindall VR
    Ann Oncol; 1990 Nov; 1(6):427-33. PubMed ID: 2083186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
    Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
    J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin in the treatment of ovarian cancer.
    Alberts DS; Mason-Liddil N
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
    Ozols RF; Behrens BC; Ostchega Y; Young RC
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group.
    Wiltshaw E; Perren TJ; Fryatt ID; Blake PR; Harper P; Slevin M
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S48-50. PubMed ID: 2189595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
    Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
    Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
    J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
    Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
    Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
    Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
    J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.